CNS Pharmaceuticals, Inc. Other Current Liabilities
CNS Pharmaceuticals, Inc. (CNSP) had Other Current Liabilities of $0 as of 2019-12-31, per its 10-K filed 2020-03-12.
Discontinued › Balance Sheet › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2020-03-12
- 2019-12-31: Other Liabilities, Current $0.00.
- 2018-12-31: Other Liabilities, Current $763.25K.
| Period end | Other Liabilities, Current |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-12 |
| 2018-12-31 | $763.25K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |